Advanced Biotherapy Inc. Appoints Thomas J. Pernice as Treasurer and Corporate Secretary and to Board of Directors.

Business Editors & Health/Medical Writers

WOODLAND HILLS, Calif.--(BUSINESS WIRE)--April 26, 2001

Advanced Biotherapy Inc. (OTCBB:ADVB) today announced that Thomas J. Pernice, managing director of the Cappello Group Inc., has been appointed as treasurer and corporate secretary, and has been appointed to the board of directors.

"We are pleased that Mr. Pernice will become an officer of the company and has been appointed to the board of directors," said Edmond F. Buccellato, chief executive officer of Advanced Biotherapy Inc. "Mr. Pernice has played a significant role over the last two years in financing and providing strategic advice for the company. His previous executive experience in private and Fortune 500 companies will continue to be a great benefit in helping us achieve the goals set by the company."

Prior to joining the Cappello Group in January 1999, Pernice served as a senior corporate executive in government and industry for more than 17 years. Most recently, Pernice was vice president, Public Affairs and a corporate officer for Dole Food Co. Inc. (NYSE:DOL), reporting to the chairman and CEO, David H. Murdock. He also served in similar capacities for the conglomerate of publicly and privately held business interests of Murdock, including the Castle & Cooke Inc. real estate company, formerly (NYSE:CCS), now privately held.

Prior to joining Dole Food Co., Pernice served in the White House for more than seven years in various capacities for the Reagan and Bush administrations. In January 1988, Pernice was appointed assistant to the vice president and director of advance in the Bush/Quayle administration. In the Reagan administration, Pernice served as a presidential advance representative to the U.S.-Soviet Summits in Moscow; Reykajavik, Iceland; and Washington, D.C., as well as the annual Seven-Nation Economic Summits.

Pernice earned a bachelor of arts degree from the University of Southern California.

The company develops drugs that may effectively treat a range of autoimmune diseases. In four randomized, placebo-controlled, double-blind trials conducted in Russia, the company has demonstrated efficacy of its anti-cytokine strategy in both RA and MS. These studies have permitted the company to determine which cytokines are most active in the autoimmune disease process, and therefore, which need to be reduced to treat the disorder.

With a five-day treatment course, statistically significant and clinically relevant responses were obtained that persisted for as long as one year after treatment termination in the MS studies and for one month in the RA studies.

The business strategy of the company involves the engagement of a corporate partner to assist in the clinical development of its drug treatments for autoimmune disorders. This will involve, upon the identification of such a partner, the filing of the necessary documents with the FDA, conducting clinical trials and obtaining the necessary regulatory approvals, (New Drug Application (NDA) or a 510K device approval).

The company does not intend to market its drug products if they are approved by the FDA, but will instead seek a licensing and royalty arrangement with a corporate partner who will market the product when and if it is approved.

Statements made in this news release, other than statements of historical fact, are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials; the progress of research and product development programs; the regulatory approval process; competitive products; future capital requirements; and the extent and breadth of the company's patent portfolio. See the company's public filings with the Securities and Exchange Commission for information about risks that may affect the company.